Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could spot hidden cancers faster and more accurately

NCT ID NCT07629609

Diagnosis Sponsor: Barbara Malene Fischer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of PET/CT scan (using [68Ga]Ga-FAPI-46) to see if it can find and stage gastroesophageal and pancreatic cancers better than current scans. About 90 adults with these cancers will get the new scan before surgery or treatment, and some will have a second scan during chemotherapy. The goal is to improve diagnosis and help doctors choose the best treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for group A 1. Male or female, over 18 years old 2. Patients with suspected pancreatic cancer based on morphological findings on standard imaging 3. CT or MRI or \[18F\]FDG PET/CT evaluated on MDT with no initial sign of distant metastases 4. Subjects must have been considered suitable for curative surgery at the time of the referral 5. Subjects must be able to read and understand the patient information in Danish to give informed consent Inclusion criteria for group B1 1. Male or female over 18 years old 2. Histological verified carcinoma from the lower esophagus, GEJ, or stomach 3. Subjects must be considered operable and resectable at the time of referral for MDT 4. Subjects must be able to read and understand the patient information in Danish to give informed consent Inclusion criteria for group B2 1. Male or female over 18 years old 2. Histological verified SRCC or PCC from the lower esophagus, GEJ, or stomach 3. Subjects with localized disease assigned to perioperative chemotherapy or subjects with metastatic disease assigned to palliative systemic treatment. 4. Subjects must be able to read and understand the patient information in Danish to give informed consent Exclusion Criteria: 1. Pregnancy or lactation 2. Weight more than the maximum limit of a PET/CT-scanner bed (140 kg) 3. History of allergic reaction due to compounds similar to the chemical composition of \[68Ga\]Ga-FAPI-46

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroesophageal cancer (GC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse type adenocarcinoma gastroesophageal cancer malignant pancreatic neoplasm Pancreatic cancer, adult pancreatic neoplasm signet ring cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastroesophageal cancer (GC) Pancreatic cancer, adult

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Rigshospitalet

    RECRUITING

    Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.